While adeno-associated virus (AAV) gene replacement therapy has transformed the prognosis for SECORD patients with RPE65 mutations, a significant portion of individuals with Severe Early Childhood Onset Retinal Dystrophy harbor mutations in other genes. For these patients, traditional gene augmentation may be unsuitable due to the large size of the mutated gene or the specific nature of the genetic defect. Antisense oligonucleotides (ASOs) are emerging as a highly promising alternative.
ASOs are short, synthetic strands of nucleic acids designed to bind to specific RNA sequences. By doing so, they can alter RNA splicing, effectively bypassing disease-causing mutations and restoring the production of functional proteins. Recent preclinical and early-phase clinical research has demonstrated the potential of intravitreal ASO injections to treat specific forms of inherited retinal diseases that share phenotypic similarities with SECORD.
One of the key advantages of ASO therapy is its ability to address deep intronic mutations that disrupt normal gene splicing. Researchers are actively developing ASO candidates targeting various genes implicated in severe early-onset retinal dystrophies. While these therapies require repeated intravitreal injections, unlike the one-time surgical administration of AAV vectors, they offer a less invasive delivery method and a targeted approach to correcting the underlying molecular defect.
As research progresses, ASOs represent a critical expansion of the therapeutic arsenal. For SECORD patients lacking RPE65 mutations, these RNA-targeted therapies provide a beacon of hope for preserving vision and halting disease progression.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.